Aspirin, Vascular Disease and Cancer: 50 Years of Controversy and the Jury’s Still Out!
Journal Title: Open Access Journal of Oncology and Medicine - Year 2018, Vol 2, Issue 1
Abstract
The story of aspirin and vascular disease starts with John O Brien, a haematologist in Portsmouth in the 1960s, who reported that the ingestion of 150mg of aspirin substantially reduced the aggregation of platelets [1]. On the basis of this finding, and the assumption that the incidence of thrombosis would be reduced, O’Brien persuaded the UK Medical Research Council in 1968 to set up a randomised trial of aspirin [2]. Three hundred and three surgical patients in four UK hospitals were randomly given 600mg aspirin or a placebo once preoperatively and on five post-operative days. The outcome was deep vein thrombosis diagnosed by I125- labelled fibrinogen. The conclusion, written presumably by Austin Heady the statistician on the team, was: ‘aspirin administration has not even a marginal effect on the frequency of DVT’. This dismissal now appears rather confident in view of the later finding of clinically important reductions by aspirin in venous thrombosis and pulmonary embolism after surgery [3]. O Brien was convinced that venous thrombosis had been an inappropriate test of aspirin in the reduction of thrombosis but he failed to persuade MRC to conduct another trial. However, persuaded by work in the Welsh National School of Medicine in the 1960s on aspirin, platelet ’clumping’ and ‘infarctoid cardiopathy’,[4-6] Archie Cochrane agreed that a trial of aspirin and vascular mortality be set up in South Wales. 1,400 postmyocardial infarction patients agreed to be randomised to 325mg aspirin orally per day the dose and frequency suggested for the trial by O’Brien.
Authors and Affiliations
Peter Elwood
Keywords
Related Articles
- EP ID EP587892
- DOI 10.32474/OAJOM.2018.02.000126
- Views 70
- Downloads 0
Breast Cancer Screening in the United Arab Emirates: Is it Time to Call for a Screening at an Earlier Age?
Cancer is a major health issue around the world, in the United Arab Emirates ( UAE ) it is the 3rd leading cause of death after cardiovascular diseases and injuries, accounting for 10% of all mortalities in the UAE in 20...
Repurposed Drugs and Nutraceutical Supplements as Neglected Complements to Cancer Treatment
In ovarian cancer there is formation of tumor cells in ovarian tissues. Lysophosphatidic acid (LPA) motivated cell proliferation, migration and endurance by acting on its cognate G-protein-coupled receptors. Lysophosphat...
Colorectal Cancer in UAE, Implications on the Screening Program 2018
a) Colorectal cancer is the fourth (4th) common cancer in both sexes, worldwide and is the third most common cancer in men and the second in women. b) In 2012, 1.36 million cases of colorectal cancer occurred and there w...
Spinal Meningioma: Pathophysiology, Diagnosis and Management
Tumors have several types that can build up in or near the spine. There are many types of spinal tumors. They can appoint the spinal cord, nerve roots or the vertebrae (bones of the spine) and pelvis. Spinal tumors have...
A Modern and Comprehensive Experimental Biospectroscopic Comparative Study on Human Common Cancers' Cells, Tissues and Tumors before and after Synchrotron Radiation Therapy
In the current study, we have experimentally and comparatively investigated and compared malignant human common cancers' cells, tissues and tumors such as Bladder Cancer, Breast Cancer, Colon and Rectal Cancer, Endometri...